USO 23284
A Phase 3, Multicenter, Randomized, Open-Label Study of Etentamig Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (M22-574)
Mga Uri ng Sakit: Lymphoma at Hematologic
Mga Kinakailangan sa Kwalipikasyon:
Eastern Cooperative Oncology Group (ECOG) performance of <= 2.
Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol.
Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment:
In participants without measurable serum or urine M protein, serum free light chain (FLC) >= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio.
Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb).
Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.
Para sa karagdagang impormasyon sa pagsubok na ito CLICK HERE .
Available sa: